All News
Dual inhibition of IL17A and IL17F in AxSpA
A new target for treatment in AxSpA is the dual inhibition of IL17A and IL17F (IL17A/F). IL17A is a key driver of the inflammation in the AxSpA and Psoriatic Arthritis (PsA). IL17A and its structurally related IL17F share biologic functional properties. Inhibition of both cytokines (IL17A/F) should result in a greater clinical benefit in AxSpA and PsA than IL17A inhibition alone.
Read Article
Vaccine Efficacy in Patients with Seronegative Spondyloarthritis
Vaccine efficacy remains an important and highly discussed topic at this year’s annual meeting given the ongoing COVID-19 global health crisis, current influenza season, and recently published 2022 ACR guidelines for vaccinations in patients with rheumatic and musculoskeletal diseases.
Read Article
ACR Best Abstracts - Day 2
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more.
Here are the RheumNow faculty selections for #ACRbest abstracts today:
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199 https://t.co/Pwg6GKu7Gg https://t.co/wPF0pu1UDa
Richard Conway RichardPAConway ( View Tweet)
Are your SpA pts planning on conceiving? Be careful with NSAID use
French study found age and NSAID use associated with longer time-to-conception.
Factors not associated: smoking, BASDAI score, DMARD use
#ACRBest Abs#1673 @RheumNow #ACR22 https://t.co/D63XTY7IB8
Robert B Chao, MD doctorRBC ( View Tweet)
Ab1673 #ACR22: Time-to-Conception (T2C) in SpA
Prosp, observ
88F, 56 pregnancy
Subfertility in 45% F, T2C 16 mos
Risks: age, NSAID
Rx: NSAIDs (26%), steroids (9%), csDMARD (14%), biol (69%)
No control grp - Is it cause or correlate?
2020 Repro G/L rec d/c NSAID
@RheumNow #ACRBest https://t.co/e51XjhyH9u
Eric Dein ericdeinmd ( View Tweet)
Hamroun et al. Preconceptual NSAID use assoc impaired fertility in SpA, HR 3.01 for time-to-conception @RheumNow #ACR22 Abstr#1673 https://t.co/jresR9MfXF https://t.co/flyfJob9un
Richard Conway RichardPAConway ( View Tweet)
Dr S Hamroun shares their study data on factors assoc w/ time-to-conception in ♀️ w/ SpA:
❗Pre-conceptional NSAID use
❗Age
Thought-provoking.
Time to re-evaluate our NSAID prescribing practices for ♀️ SpA?
#ACR22 @RheumNow ABST#1673 https://t.co/cHED0I3vUe
sheila RHEUMarampa ( View Tweet)
Dr. Ogdie proposes a whole-patient care approach to the treat-to-target strategy in SpA with QoL as the most important target.
#ACR22 @Rheumnow @rheumarhyme @trishiemd https://t.co/GjLt2Nym3I
sheila RHEUMarampa ( View Tweet)
L14 #ACR22 Bimekizumab BE MOBILE 1 and 2
Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nrAxSpA, 45% AS) to W52 (61%, 58%). Efficacy in TNF-naive & TNF-failure.
AEs: Nasopharyngitis (12% nrAxSpA, 9% AS), URI (9, 6%), candidiasis (7, 6%), COVID (7, 2%)
@RheumNow https://t.co/G31PrfqtVu
Eric Dein ericdeinmd ( View Tweet)
L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS
P3b: SEC 150 mg v SEC 300 v SDZ-ADL
Wk 104: no radiographic progression in 66%, 67%, 66% - no statistical significance
Hard to assess as overall, low rate of progression
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
Does tofacitinib work better in patients with PsA and AS who smoke?
Abstract #1036 #ACR22 @RheumNow
🚬519 ever smokers
🚭767 never smokers
💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO
✋Overall, efficacy was generally comparable in ever v. never 🚬
Catherine Sims, MD DrCassySims ( View Tweet)
Abstract #PP25
Patient mantra on life with SpA: “not to over-exert the body on your good days and always strive to be active on your bad days”
Patient recommended exercise:
🏓table tennis
🏊♂️swimming
🧘yoga
🤸tai chi
#ACR22 @RheumNow
Catherine Sims, MD DrCassySims ( View Tweet)
Bimekizumab (BKZ) in AxSpA to Wk52
◦ sustained efficacy
◦ suppression of inflammation
◦ improvements in function and quality of life
◦ no new safety signals were observed
◦ consistent with the safety profileWk24 data
Baraliakos #L14 https://t.co/gk23g4vqQl #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Mortality in patients with SpA
Abstract #0569 #ACR22 @RheumNow
✏️systematic review/meta-analysis of 19 studies
✋No increased mortality in patients with PsA compared to gen. pop.
🦠Infection, 🫀CV, and 🫁 pulm. specific mortality sig. higher in PsA patients
Catherine Sims, MD DrCassySims ( View Tweet)
Karmacharya @rheum_cat et al. Comorbidity clusters in AS. Depression cluster associated higher disease activity and worse function over time. @RheumNow #ACR22 Abstr#1609 https://t.co/lFVoyhy5UQ https://t.co/26EjzXULGr
Richard Conway RichardPAConway ( View Tweet)
Spinal lesions on MRI in axSpA is ~3% in patients with negative imaging in SIJ on MRI or X-ray. Agreement in >5/9 central readers. Frequency of spinal vertebral corner BME lesions was significantly higher these cases. Maksymovych Abs#2257 https://t.co/56yxGxBgLp #ACR22 @RheumNow https://t.co/CkJ9o2dJuT
Dr. Antoni Chan synovialjoints ( View Tweet)
Does lifestyle impact Tx. response?
#Abstr 1510 looked at effect of lifestyle on TNFi response in #axSpA
- The study found higher BMI (obese, overweight) and smoking were less likely to respond to TNFi
- Important to discuss lifestyle when starting tx.
@RheumNow #ACR22 https://t.co/z98DFMLxu3
Akhil Sood MD AkhilSoodMD ( View Tweet)
@RheumNow video from #ACR22
Opioid use in PsA and SpA patients
Discussing abstract 1012 by @AlexisOgdie
https://t.co/fKRog1aIkH
Eric Dein ericdeinmd ( View Tweet)
Jones et al. Non-smokers, normal BMI, and current drinkers! with AxSpA more likely to respond to TNFi. @RheumNow #ACR22 Abstr#1510 https://t.co/inCz2sAyj5 https://t.co/K27ptuLV7Y
Richard Conway RichardPAConway ( View Tweet)
